Company intelligence / Profile preview

Day One Regenerative Science

South San Francisco, California, United Statesregeneron.com ↗

Ownership: Private
Development stage: Other

Overview

OJEMDA™ has been launched commercially with reported net product revenue in preliminary financial results for FY2024. The company focuses on targeted therapies for pediatric and adult cancers. No detailed clinical trial data provided in search results.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Day One Regenerative Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Day One Regenerative Science.

Explore the full profile